Drug
Sel 212 Low Dose
Sel 212 Low Dose: highest development phase Phase 3, developed by Swedish Orphan Biovitrum. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| SEL-212 low-dose NCT04513366 | Phase 3 | Chronic Gout |
Latest
No recent events.
Follow Sel 212 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.